EN DE
STOCK COMPARISON

Chorokbaem Healthcare Co vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Chorokbaem Healthcare Co (118000) and Eli Lilly and (LLY) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Chorokbaem Healthcare Co trades at KRW 1,273 versus a fair value of KRW 511 (-60%), while Eli Lilly and trades at $1,182 versus $792 (-33%).
Chorokbaem Healthcare Co
118000.KO · KRW · Health Care
-60%
upside to fair value
overvalued
PriceKRW 1,273
Fair ValueKRW 511
Quality37/100
Eli Lilly and
LLY · USD · Health Care
-33%
upside to fair value
overvalued
Price$1,182
Fair Value$792
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Chorokbaem Healthcare CoEli Lilly and
Valuation
n/aP/E (TTM)40.9×
n/aP/S (TTM)14.31×
n/aP/B38.95×
4.5×EV/EBITDA29.5×
n/aPEG1.54×
−59.8%Fair value upside−33.0%
n/aDividend yield0.5%
n/aDividend per share$6.46
Profitability
6%Operating margin49%
n/aEBIT margin trend (5Y)1.42×
0%Return on equity107%
0%Return on assets21%
Growth
69%Revenue growth (YoY)56%
19.8%Avg. growth/yr (3Y)31.7%
4.1%Avg. growth/yr (5Y)21.6%
−27.7%Value creation/yr+26.5%
Balance & size
0.5×Interest coverage (EBIT/interest)37.3×
0.19×Debt / equity1.54×
$16MMarket cap$1.0T
expensiveGrowth qualitymixed

Eli Lilly and leads: 2 to 8 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Chorokbaem Healthcare Coof which business quality 37 · market factors 68 Eli Lilly andof which business quality 64 · market factors 81
ProfitabilityMargins and returns on capital today
13
85
Quality GrowthAre margins and returns improving?
34
86
CashflowEarnings quality: real cash, not paper profit
34
51
Fin. StrengthBalance sheet, leverage, solvency risk
35
53
InvestmentDisciplined investing over empire-building
54
15
Low VolatilityCalm price path (market factor)
47
77
MomentumPrice trend over the last 3–12 months (market factor)
77
77
52W MomentumDistance to the 52-week high (market factor)
76
91
Net IssuanceShare count: buybacks or dilution?
69
86

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyChorokbaem Healthcare CoPrice KRW 1,273Eli Lilly andPrice $1,182
DCF Modelsn/a-71%below the price$345
Earnings-Based-78%below the priceKRW 286-80%below the price$239
Dividend Discountn/a-90%below the price$115
Multiples-61%below the priceKRW 493-70%below the price$358
Asset-Based+266%above the priceKRW 4,658-98%below the price$19.94
Growth DCFn/a-83%below the price$197
Economic Profit+228%above the priceKRW 4,173-71%below the price$347
Growth Earnings-60%below the priceKRW 511-68%below the price$375
Minimum-78%below the priceKRW 286-98%below the price$19.94
Maximum+266%above the priceKRW 4,658-68%below the price$375
Median-60%below the priceKRW 511-75%below the price$292
Geometric mean-16%below the priceKRW 1,070-84%below the price$190

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Chorokbaem Healthcare Co: 8 of 11 models see the stock below the current price.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Chorokbaem Healthcare Co
Price KRW 1,273
Fair Value KRW 511
Bear KRW 370Bull KRW 798
Eli Lilly and
Price $1,182
Fair Value $792
Bear $401Bull $1,165

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Chorokbaem Healthcare Co · Health Care

Quality score37 · bottom 25%
Fair value upside-60% · below median

Eli Lilly and · Health Care

Quality score67 · Top 25%
Fair value upside-33% · below median

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Chorokbaem Healthcare Co trades at KRW 1,273 versus a fair value of KRW 511 (-60%), while Eli Lilly and trades at $1,182 versus $792 (-33%).

Eli Lilly and has the higher quality score (67/100).

Open Eli Lilly and live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.